Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subjects with history of mild atopic asthma between 18 and 60 years-of-age
Body mass index (BMI) between 18 and 35 kg/m\^2
Normal or clinically acceptable physical examination (PE), clinical laboratory values, and electrocardiogram (ECG); clinically acceptable PE includes history of mild atopic asthma
Used only inhaled short-acting β2-agonists infrequently to treat asthma
No current exposure to allergens to which subject experiences asthmatic responses
No other lung disease, exacerbations of asthma or lower respiratory tract infections for at least 6 weeks prior to screening
Positive skin prick test to common aeroallergens at screening
You may not be if
History or evidence of a clinically significant disorder (including psychiatric), condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion;
History or current medical conditions that are contraindicated for methacholine challenge, such as myocardial infarction or stroke within previous 3 months, known cardiac disease, uncontrolled hypertension and aortic or cerebral aneurysm
Evidence of active or suspected bacterial, viral, fungal or parasitic infections within past 6 weeks
Subject has know type I/II diabetes
History of residential exposure to tuberculosis or has a positive purified protein derivative (PPD) or QuantiFERON test within 4 weeks before randomization
Subject who has history of malignancy of any type within 5 years prior to enrollment
Subjects tested positive for drugs/alcohol or nicotine use at screening
Subjects tested positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Clareo Health | Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma
